

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **PROFIT WARNING**

This announcement is made by MicroPort Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Part XIVA of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform holders of the Company’s shares and securities and potential investors that, based on the unaudited consolidated financial statements, despite the reduction in elective surgeries at medical institutions due to the COVID-19 pandemic, the Group achieved a steady increase in sales revenue for the six months ended 30 June 2022 (the “**Reporting Period**”), which was principally attributable to the steady growth in overseas businesses such as the orthopedics business and the CRM business (excluding the effect of exchange rates) as well as the rapid market penetration in the endovascular and peripheral vascular devices business, the neurovascular business and the heart valve business, and the contribution from new product launches.

During the Reporting Period, the Group recorded loss attributable to equity shareholders of the Company of between approximately USD193 million and USD203 million, as compared with a loss of approximately USD90.3 million for the same period last year. This change was principally attributable to (i) the increase in non-cash expenses, including the accrued interest on the convertible bonds issued by the Group and the preference shares issued by subsidiaries, the increase in costs recognized for the incentive shares and underlying shares granted to certain employees under the Group’s share incentive schemes, as well as the effect of widening losses of equity-accounted investees during the Reporting Period; (ii) significant increases in expenses for the surgical robot business, the heart valve business, the surgical business and other business segments in their active promotion of research and development, registration and commercialization with the help of their own independent financing channels; and (iii) increase in investment in overseas market development and product promotion.

As at the date of this announcement, the Company is still in the process of preparing and completing the unaudited interim results of the Group for the six months ended 30 June 2022 (the “**2022 Interim Results**”). The information contained in this announcement is a preliminary assessment made by the Board based on the latest management accounts of the Group which have not been audited or reviewed by the independent auditors or the audit committee of the Company. Holders of the Company’s shares and securities and potential investors are advised to read the Company’s announcement for the 2022 Interim Results carefully, which is expected to be published before the end of August 2022.

**Holders of the Company’s shares and securities and potential investors are advised to exercise caution when dealing in the shares and securities of the Company.**

By Order of the Board  
**MicroPort Scientific Corporation**  
*Chairman*  
**Dr. Zhaohua Chang**

Shanghai, the PRC, 5 August 2022

*As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Mr. Norihiro Ashida, Dr. Yasuhisa Kurogi and Mr. Hongliang Yu; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.*

\* *for identification purpose only*